Drugs Containing Excipient (Inactive Ingredient) TREHALOSE

Branded drugs containing TREHALOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Liquidia Technologies Inc	YUTREPIA	treprostinil	72964-011	TREHALOSE DIHYDRATE	2037-05-05
Apellis Pharmaceuticals Inc	SYFOVRE	pegcetacoplan	73606-020	TREHALOSE DIHYDRATE	2033-11-15

Generic drugs containing TREHALOSE excipient

Company	Ingredient	NDC	Excipient
AbbVie Inc	pivekimab sunirine-pvzy	0074-0282	TREHALOSE
GlaxoSmithKline LLC	belantamab mafodotin	0173-0913	TREHALOSE
AstraZeneca Pharmaceuticals LP	tremelimumab	0310-4505	TREHALOSE

Trehalose Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 15, 2026

Trehalose is a pharmaceutical excipient with its strongest commercial position in biologics stabilization, lyophilized products, vaccines, cell and gene therapy formulations, and certain ophthalmic and parenteral products. Its financial trajectory is tied less to conventional tablet volumes than to biologics approvals, drug-product outsourcing, sterile manufacturing capacity and demand for stable temperature-sensitive products.

The market has attractive technical economics but limited public financial transparency. Trehalose suppliers generally report sales within broader carbohydrate, bioprocessing or life-science segments rather than as a standalone product line. No authoritative, audited global revenue figure exists for pharmaceutical-grade trehalose alone.

What is trehalose and how is it used as a pharmaceutical excipient?

Trehalose is a nonreducing disaccharide composed of two glucose units. Pharmaceutical suppliers sell it primarily as trehalose dihydrate, although anhydrous material is also available.

Attribute	Pharmaceutical relevance
Chemical name	Alpha-D-glucopyranosyl-alpha-D-glucopyranoside
Common form	Trehalose dihydrate
CAS number	99-20-7 for trehalose; 6138-23-4 for trehalose dihydrate
Primary function	Stabilizer, bulking agent, cryoprotectant and lyoprotectant
Main dosage forms	Injectable, lyophilized, ophthalmic and biotechnology products
Key mechanism	Protects proteins, membranes and viral or cellular structures during freezing, drying and reconstitution
Regulatory status	Established pharmaceutical excipient with compendial and regulatory-use history
Main demand driver	Biologics and complex injectable products

Trehalose stabilizes proteins through hydrogen bonding and replacement of water during drying or freezing. Its low reducing activity reduces the risk of Maillard reactions compared with reducing sugars such as glucose or lactose. This property is important in formulations containing proteins, peptides, viral vectors and other sensitive biological materials.

What formulations are protected by trehalose?

Trehalose is used in formulation platforms that require protection against:

• Freeze-thaw stress
• Lyophilization stress
• Protein aggregation
• Loss of biological activity
• Membrane disruption
• Viral-vector degradation
• Reconstitution instability
• Temperature excursions during transportation

Trehalose is usually combined with surfactants, buffers, amino acids, polymers or other sugars. It can act as a bulking agent in a freeze-dried cake, but its primary commercial value is stabilization rather than low-cost mass filling.

How large is the pharmaceutical trehalose market?

The pharmaceutical-grade segment is materially smaller than the total trehalose market, which also includes food, cosmetics, animal health, agriculture and research applications. Published market reports often combine these end uses and produce non-comparable estimates.

The absence of standalone reporting by major suppliers creates three valuation problems:

1. Pharmaceutical-grade sales are not separated from food-grade and industrial trehalose.
2. Contract manufacturing and formulation services capture part of the value created by trehalose without reporting it as excipient revenue.
3. Higher-value sterile or custom-grade material is mixed with bulk powder in market estimates.

A practical market model therefore separates the sector into four revenue pools.

Revenue pool	Commercial characteristics	Margin profile
Bulk pharmaceutical-grade powder	Compendial or customer-qualified material	Low to moderate
High-purity biotechnology grade	Used in biologics and process development	Moderate to high
Sterile or controlled bioprocess material	Requires greater quality and supply controls	High
Formulation and CDMO services	Trehalose incorporated into proprietary drug products	Highest value capture, but not reported as trehalose revenue

The underlying volume market is likely driven by a relatively small number of large biologics manufacturers and a much larger group of development-stage companies. Revenue growth can therefore occur through qualification wins and new-product launches without a proportional increase in tonnage.

What is driving trehalose pharmaceutical demand?

Biologics expansion

Monoclonal antibodies, recombinant proteins, vaccines, peptides and nucleic-acid products require excipients that maintain structural and functional integrity. Trehalose is positioned for products in which sucrose, mannitol or sorbitol do not provide the required stabilization profile.

Biologics manufacturers often qualify multiple excipients during development. Once a formulation is locked and approved, changing the excipient may require comparability work, stability data and regulatory submissions. This creates customer retention and switching costs for qualified suppliers.

Growth in lyophilized injectables

Lyophilization remains common for products that cannot maintain adequate shelf life in liquid form. Trehalose can improve cake structure and protect the active ingredient through freezing, primary drying and secondary drying.

Demand is strongest in:

• Injectable biologics
• Peptide products
• Vaccines
• Recombinant enzymes
• Antibody-drug conjugate components
• Cell and gene therapy materials
• Diagnostic and research reagents

Cell and gene therapy

Trehalose is used in some cell-processing, cryopreservation and viral-vector workflows. This market is commercially important even where volumes are low because the material must meet stringent identity, impurity, endotoxin and microbial specifications.

Cell and gene therapy demand remains exposed to clinical attrition, manufacturing scale-up delays and reimbursement constraints. The segment creates high-value technical opportunities but does not yet provide the same volume stability as established antibody products.

Temperature-sensitive supply chains

Trehalose can reduce dependence on strict cold-chain conditions in selected formulations. It does not eliminate cold-chain requirements, but it can improve stability during shipping and short-term temperature excursions.

This is commercially relevant for emerging-market distribution, decentralized treatment models and products shipped through complex logistics networks.

Who supplies pharmaceutical-grade trehalose?

The supplier base is concentrated in companies with carbohydrate manufacturing, pharmaceutical quality systems or bioprocessing capabilities.

Supplier or supplier group	Relevant position
Hayashibara, part of Nagase & Co.	Established trehalose producer with pharmaceutical and biotechnology applications
Pfanstiehl	High-purity excipient and bioprocessing supplier serving pharmaceutical customers
DFE Pharma and other excipient distributors	Distribution, technical support and formulation access in selected regions
Chinese and other Asian manufacturers	Cost-competitive bulk and pharmaceutical-grade supply
Specialty distributors	Regional supply, qualification support and smaller-batch access

Hayashibara has historically been one of the best-known commercial trehalose producers. Nagase reports Hayashibara within broader life-science and specialty-material activities rather than publishing a standalone pharmaceutical trehalose income statement (Nagase & Co., 2024).

Pfanstiehl’s position is based on high-purity excipients and raw materials for biopharmaceutical manufacturing. Its commercial differentiation is quality documentation, regulatory support, supply reliability and customer qualification rather than commodity pricing alone (Pfanstiehl, 2024).

How does pharmaceutical-grade trehalose compete with sucrose and mannitol?

Attribute	Trehalose	Sucrose	Mannitol
Protein stabilization	Strong in many freeze-dried systems	Strong and widely established	Formulation-dependent
Reducing sugar risk	Low	Low	Low
Bulking performance	Moderate	Moderate	Strong
Existing regulatory familiarity	High but narrower than sucrose	Very high	Very high
Cost position	Usually higher than commodity alternatives	Competitive	Competitive
Typical use	Stabilization and cryoprotection	Stabilization and bulking	Bulking, tonicity and crystallizing systems
Main competitive advantage	Broad protection during drying and freezing	Established use and low switching risk	Physical structure and cost

Trehalose wins where its stabilization performance justifies the higher material cost or avoids development compromise. It loses where a lower-cost excipient provides adequate stability, where the formulation requires strong bulking properties, or where the sponsor wants to minimize regulatory and supply-chain complexity.

What is the financial trajectory for pharmaceutical trehalose?

The base-case financial trajectory is positive, with growth concentrated in premium grades and formulation-intensive applications rather than commodity volume.

Near-term trajectory

Near-term growth depends on:

• Commercial biologics launches
• Expansion of lyophilized injectable capacity
• Increased outsourcing to CDMOs
• Development of vaccines and viral-vector products
• Qualification of regional and dual-source suppliers
• Demand for higher-purity and low-endotoxin grades

Revenue is likely to be resilient in established biologics but volatile in cell and gene therapy. Development programs can generate high technical demand before declining sharply if clinical programs fail.

Medium-term trajectory

Over a three- to seven-year horizon, the highest-value opportunities are likely to come from:

1. Sterile and low-endotoxin grades.
2. Excipient systems validated for specific biologic classes.
3. Custom particle-size and moisture specifications.
4. Trehalose-containing lyophilization platforms.
5. Cell-processing and viral-vector applications.
6. Regional supply agreements with large biologics manufacturers.

Commodity pharmaceutical-grade powder will face price pressure as Asian capacity expands. Suppliers with only standard powder are more exposed to substitution and procurement competition.

Margin outlook

Trehalose has a favorable value-to-volume profile in qualified applications. The raw material is not intrinsically scarce, but customers incur significant costs when changing a validated excipient supplier.

Margins are supported by:

• Compendial compliance
• Batch-to-batch consistency
• Low bioburden and endotoxin control
• Documentation packages
• Regulatory change control
• Audit readiness
• Reliable delivery
• Technical formulation support

Margins are threatened by:

• Capacity additions in China and other Asian markets
• Long-term procurement tenders
• Customer dual-sourcing programs
• Substitution by sucrose or mannitol
• Lower demand from failed development programs
• Greater use of liquid biologic formulations that avoid lyophilization

What is the FDA regulatory status of trehalose?

Trehalose is an established excipient, but regulatory acceptance is product-specific. The FDA evaluates the safety and suitability of an excipient in the context of the finished drug, route of administration, dose and formulation.

The FDA Inactive Ingredient Database is a key reference for identifying prior use by route and dosage form. Presence in the database supports regulatory precedent but does not guarantee approval for every concentration or administration route (U.S. Food and Drug Administration, 2024).

Trehalose may also be supported by:

• USP-NF or other pharmacopeial specifications
• Drug Master File documentation
• Manufacturer quality and impurity data
• Toxicology packages
• Extractables and leachables assessments where relevant
• Endotoxin and microbial-control data
• Stability and compatibility studies

For a new route, unusual dose or advanced therapy application, the sponsor may need additional justification despite trehalose’s established history.

Does trehalose have an Orange Book listing?

No. Trehalose is an excipient, not an active pharmaceutical ingredient with an independent FDA Orange Book exclusivity record. It does not have standalone Orange Book patents, Hatch-Waxman exclusivity or Paragraph IV litigation.

Any patent protection involving trehalose generally attaches to the finished formulation, method of treatment, delivery system, manufacturing process or combination of excipients.

What patents protect pharmaceutical formulations containing trehalose?

Trehalose itself is a well-known chemical and is unlikely to provide meaningful modern composition-of-matter exclusivity. Commercial protection typically arises from:

• Specific trehalose concentrations
• Protein-to-trehalose ratios
• Trehalose combined with surfactants or amino acids
• Stabilized lyophilized cakes
• Viral-vector formulations
• Cell-preservation media
• Ophthalmic delivery systems
• Dry-powder inhalation formulations
• Manufacturing and drying processes
• Specific therapeutic uses

How strong is the patent estate for trehalose?

The patent estate is fragmented rather than concentrated around the excipient. Strength depends on claim scope, disclosure of alternative sugars, clinical relevance and whether the claims cover a commercially important active ingredient.

IP category	Typical strength
Trehalose molecule	Weak, largely prior-art constrained
Trehalose as a general stabilizer	Weak to moderate
Defined biologic formulation	Moderate to strong if narrowly drafted and clinically relevant
Lyophilization process	Moderate, with design-around risk
Cell and gene therapy formulation	Potentially strong but dependent on evolving prior art
Manufacturing method	Variable; often vulnerable to alternative process routes
Finished product method-of-use patent	Potentially strong if tied to approved indication

Patent risk should be assessed at the product level rather than by searching for “trehalose patents” alone. A generic or biosimilar entrant would normally challenge the relevant finished-drug patents, not an excipient patent.

When does trehalose lose exclusivity?

Trehalose has no single exclusivity-loss date. The molecule is off-patent as a basic chemical, and its commercial protection derives from individual formulation, process and product patents.

A typical protection timeline is:

Protection layer	Expected commercial effect
Basic chemical and general use	Minimal current exclusivity
Supplier manufacturing process	May restrict direct replication but often allows design-around
Proprietary formulation	Can delay competing finished products
Approved product patent	May affect generic or biosimilar launch timing
Trade secrets and quality systems	Can preserve supply relationships after patent expiry
Regulatory precedent	Reduces development cost for competitors

Which companies are challenging the trehalose market?

Competition is primarily commercial rather than litigation-driven. The main challengers are:

• Low-cost Asian producers
• Established excipient manufacturers expanding into biologics
• Distributors offering dual-source alternatives
• CDMOs that internalize formulation and excipient procurement
• Suppliers of sucrose, mannitol and specialized polymers
• Sponsors developing liquid formulations that reduce dependence on lyophilization

There is no broad Paragraph IV litigation trend centered on trehalose. Competitive pressure appears through supplier qualification, pricing, technical substitution and contract renewal.

What generic entry risks exist for trehalose-containing drugs?

Generic entry risk is determined by the finished product’s active ingredient and patent estate.

For small-molecule products, an abbreviated new drug application may rely on an established formulation or use a permissible excipient variation. For biologics, biosimilar sponsors must address analytical similarity, manufacturing comparability and product-specific regulatory requirements.

Trehalose can create formulation complexity because:

• Small concentration changes may affect stability.
• A substitute sugar may alter reconstitution or aggregation behavior.
• Lyophilized cake structure may change.
• Excipients can affect immunogenicity and potency assays.
• A formulation patent may claim the trehalose combination directly.

Trehalose therefore raises development and comparability costs in some products, but it does not independently block generic or biosimilar entry.

What licensing deals affect pharmaceutical trehalose?

Publicly disclosed licensing deals specifically for pharmaceutical trehalose are limited. The commercial model is usually supply, distribution, quality agreement or joint development rather than a high-profile molecule license.

The most important contractual instruments are:

• Long-term supply agreements
• Dual-source qualification agreements
• Technology-transfer arrangements
• CDMO formulation agreements
• Drug Master File access
• Regional distribution contracts
• Custom-grade development agreements

Supplier lock-in is more likely to arise from qualification history and manufacturing know-how than from a publicly visible patent license.

What manufacturing and geographic risks affect trehalose supply?

Trehalose is produced industrially from starch-derived glucose through enzymatic conversion and purification. The production process is established, but pharmaceutical supply requires controls beyond simple carbohydrate manufacture.

Key barriers include:

• Consistent crystallization and hydrate control
• Moisture specification
• Residual impurity control
• Microbial and endotoxin management
• Batch traceability
• Validated analytical methods
• Change-control discipline
• Regional regulatory documentation
• Reliable shipping and packaging

Asia remains important for production capacity and cost competitiveness. North American and European customers often place greater value on local technical support, regulatory documentation and supply redundancy.

Geographic concentration is a risk where a sponsor relies on one plant, one qualified grade or one shipping corridor. Dual sourcing can reduce interruption risk but may require comparative stability and process-validation work.

What is the commercial outlook for trehalose versus competing excipients?

Trehalose should outperform in technically demanding biologic formulations but underperform in high-volume, cost-sensitive applications.

Market condition	Likely trehalose outcome
Growth in lyophilized antibodies	Positive
Expansion of vaccines and viral vectors	Positive
Greater use of liquid biologics	Negative to neutral
Strong CDMO investment	Positive
Commodity excipient price competition	Negative
Cell and gene therapy approvals	High upside, high volatility
Regulatory preference for established excipients	Mixed
Increased dual sourcing	Volume-positive, price-negative

The most defensible investment thesis is a premium-grade, biologics-focused supplier with strong quality systems and multiple qualified manufacturing sites. A commodity-volume strategy faces greater price and substitution risk.

Key Takeaways

• Trehalose is an established excipient used mainly for stabilization, cryoprotection and lyophilization of biologics.
• Pharmaceutical-grade trehalose is a smaller and more valuable segment than the broader food and industrial trehalose market.
• Public companies generally do not report pharmaceutical trehalose revenue separately.
• Growth is linked to biologics, vaccines, lyophilized injectables, viral vectors and cell-processing applications.
• Premium sterile, low-endotoxin and biotechnology grades should have better margins than standard powder.
• Sucrose and mannitol remain major substitutes because of cost, regulatory familiarity and broad formulation precedent.
• Trehalose itself has little current standalone patent value. Commercial IP usually covers finished formulations, manufacturing processes or therapeutic uses.
• There is no standalone Orange Book exclusivity or Paragraph IV litigation for trehalose.
• Supplier qualification, quality systems and technical documentation are more important competitive barriers than basic chemistry.
• The highest commercial risk is price erosion in standard grades and demand volatility in development-stage advanced therapies.

Frequently Asked Questions

Is trehalose a high-margin pharmaceutical excipient?

It can be high margin in sterile, low-endotoxin, biotechnology and custom-qualified grades. Standard pharmaceutical-grade powder is more exposed to commodity pricing.

Can trehalose be replaced by sucrose in biologic formulations?

Sometimes, but substitution requires comparative formulation, stability and process data. Trehalose and sucrose can produce different aggregation, cake-structure and reconstitution outcomes.

Is trehalose used in mRNA vaccines?

Trehalose has been investigated and used in nucleic-acid and nanoparticle stabilization systems, but the excipient composition varies by product. Regulatory assessment is product-specific.

Does trehalose create biosimilar barriers?

Trehalose does not independently create biosimilar exclusivity. It can increase formulation-development and comparability complexity when the reference product depends on a trehalose-containing formulation.

What is the most attractive trehalose investment segment?

The strongest risk-adjusted segment is high-purity, biologics-grade supply supported by regulatory documentation, redundant manufacturing capacity and technical formulation services.

References

1. Nagase & Co., Ltd. (2024). Integrated report 2024. https://www.nagase.co.jp
2. Pfanstiehl, Inc. (2024). Pharmaceutical excipients and biopharmaceutical raw materials. https://www.pfanstiehl.com
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. U.S. Food and Drug Administration. (2024). Drug Master Files guidance and pharmaceutical quality resources. https://www.fda.gov
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
6. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.